UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 39

Sortiert nach

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

Cancer Immunology, Immunotherapy, 2016-04, Vol.65 (4), p.485-492

2016

Link zum Volltext

Verfügbarkeit prüfen

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

Frontiers in immunology, 2017-05, Vol.8, p.533-533

2017

Link zum Volltext

Verfügbarkeit prüfen

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Frontiers in immunology, 2019-11, Vol.10, p.2683-2683

2019

Link zum Volltext

Verfügbarkeit prüfen

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies

Cancer Immunology, Immunotherapy, 2018-01, Vol.67 (1), p.25-38

2018

Link zum Volltext

Verfügbarkeit prüfen

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma

Cytotherapy (Oxford, England), 2017-02, Vol.19 (2), p.235-249

2017

Link zum Volltext

Verfügbarkeit prüfen

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia

Frontiers in immunology, 2020-01, Vol.10, p.3123-3123

2020

Link zum Volltext

Verfügbarkeit prüfen

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

Frontiers in immunology, 2020-10, Vol.11, p.581468-581468

2020

Link zum Volltext

Verfügbarkeit prüfen

A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma

Frontiers in immunology, 2017-06, Vol.8, p.676-676

2017

Link zum Volltext

Verfügbarkeit prüfen

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer

Frontiers in immunology, 2023-10, Vol.14, p.1254821-1254821

2023

Link zum Volltext

Verfügbarkeit prüfen

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity

Journal for immunotherapy of cancer, 2021-10, Vol.9 (10), p.e002980

2021

Link zum Volltext

Verfügbarkeit prüfen

Innate-like NKp30+CD8+ T cells armed with TCR/CAR target tumor heterogeneity

Oncoimmunology, 2021-01, Vol.10 (1), p.1973783-1973783

2021

Link zum Volltext

Verfügbarkeit prüfen

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

Cancer Immunology, Immunotherapy, 2008-03, Vol.57 (3), p.411-423

2008

Link zum Volltext

Verfügbarkeit prüfen

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma

Frontiers in immunology, 2023-08, Vol.14, p.1228894-1228894

2023

Link zum Volltext

Verfügbarkeit prüfen

Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system

PloS one, 2013-08, Vol.8 (8), p.e72756-e72756

2013

Link zum Volltext

Verfügbarkeit prüfen

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity

Frontiers in immunology, 2022-01, Vol.12, p.798087-798087

2022

Link zum Volltext

Verfügbarkeit prüfen

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

Journal for immunotherapy of cancer, 2024-02, Vol.12 (2), p.e008155

2024

Link zum Volltext

Verfügbarkeit prüfen

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

Cancer Immunology, Immunotherapy, 2012-09, Vol.61 (9), p.1451-1461

2012

Link zum Volltext

Verfügbarkeit prüfen

Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28-29 2017, Doha, Qatar)

Journal of translational medicine, 2018-10, Vol.16 (1), p.276-276, Article 276

2018

Link zum Volltext

Verfügbarkeit prüfen

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

Oncoimmunology, 2016-04, Vol.5 (4), p.e1119354-e1119354

2016

Link zum Volltext

Verfügbarkeit prüfen

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

Oncoimmunology, 2013-10, Vol.2 (10), p.e26527-e26527

2013

Link zum Volltext

Verfügbarkeit prüfen

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

Cancer Immunology, Immunotherapy, 2023-09, Vol.72 (9), p.2905-2918

2023

Link zum Volltext

Verfügbarkeit prüfen

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors

The Journal of immunology (1950), 2015-09, Vol.195 (5), p.2493-2501

2015

Link zum Volltext

Verfügbarkeit prüfen

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

Cancer Immunology, Immunotherapy, 2015-05, Vol.64 (5), p.621-634

2015

Link zum Volltext

Verfügbarkeit prüfen

Arming NK cells with enhanced antitumor activity: CARs and beyond

Oncoimmunology, 2013-08, Vol.2 (8), p.e25220-e25220

2013

Link zum Volltext

Verfügbarkeit prüfen

Selective Induction of Cancer Cell Death by Targeted Granzyme B

Antibodies, 2013-03, Vol.2 (4), p.130-151

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 39

Suche als RSS-Feed

Aktive Filter

ThemaImmunology

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(38)
Mit Volltextzugriff
(37)

Publikationsform

Artikel
(39)

Sprache

Englisch
(39)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

14 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

NK-92: an ‘off-the-shelf therapeutic’ for adoptive natural killer cell-based cancer immunotherapy

Chimeric Antigen Receptor-Engineered NK-92 Cells: An Off-the-Shelf Cellular Therapeutic for Targeted Elimination of Cancer Cells and Induction of Protective Antitumor Immunity

CAR-Engineered NK Cells for the Treatment of Glioblastoma: Turning Innate Effectors Into Precision Tools for Cancer Immunotherapy

Clinical grade manufacturing of genetically modified, CAR-expressing NK-92 cells for the treatment of ErbB2-positive malignancies

Continuously expanding CAR NK-92 cells display selective cytotoxicity against B-cell leukemia and lymphoma

High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia

ERBB2-CAR-Engineered Cytokine-Induced Killer Cells Exhibit Both CAR-Mediated and Innate Immunity Against High-Risk Rhabdomyosarcoma

A Two-Phase Expansion Protocol Combining Interleukin (IL)-15 and IL-21 Improves Natural Killer Cell Proliferation and Cytotoxicity against Rhabdomyosarcoma

Preclinical assessment of CAR-NK cell-mediated killing efficacy and pharmacokinetics in a rapid zebrafish xenograft model of metastatic breast cancer

Bispecific antibody-mediated redirection of NKG2D-CAR natural killer cells facilitates dual targeting and enhances antitumor activity

Innate-like NKp30+CD8+ T cells armed with TCR/CAR target tumor heterogeneity

Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells

ErbB2 (HER2)-CAR-NK-92 cells for enhanced immunotherapy of metastatic fusion-driven alveolar rhabdomyosarcoma

Vaccination directed against the human endogenous retrovirus-K envelope protein inhibits tumor growth in a murine model system

CD33 Delineates Two Functionally Distinct NK Cell Populations Divergent in Cytokine Production and Antibody-Mediated Cellular Cytotoxicity

CAR-mediated targeting of NK cells overcomes tumor immune escape caused by ICAM-1 downregulation

Expression of IL-15 in NK cells results in rapid enrichment and selective cytotoxicity of gene-modified effectors that carry a tumor-specific antigen receptor

Tailoring cells for clinical needs: Meeting report from the Advanced Therapy in Healthcare symposium (October 28-29 2017, Doha, Qatar)

Dual targeting of glioblastoma with chimeric antigen receptor-engineered natural killer cells overcomes heterogeneity of target antigen expression and enhances antitumor activity and survival

Retargeting NK-92 cells by means of CD19- and CD20-specific chimeric antigen receptors compares favorably with antibody-dependent cellular cytotoxicity

Multivalent adaptor proteins specifically target NK cells carrying a universal chimeric antigen receptor to ErbB2 (HER2)-expressing cancers

Exclusive Transduction of Human CD4+ T Cells upon Systemic Delivery of CD4-Targeted Lentiviral Vectors

Disialoganglioside-specific human natural killer cells are effective against drug-resistant neuroblastoma

Arming NK cells with enhanced antitumor activity: CARs and beyond

Selective Induction of Cancer Cell Death by Targeted Granzyme B

Aktive Filter

Suchergebnisse filtern